Human insulin drugs are used for the treatment of diabetes. These drugs help in controlling blood glucose levels in patients. They are administered through various delivery methods such as injections, pumps, and inhalers. Injections are most commonly used delivery method for human insulin drugs. Common insulin products available in the market include rapid acting insulin, short acting insulin, intermediate acting insulin, long acting insulin, and premixed insulin.

The global human insulin drug market is estimated to be valued at US$ 56921.85 Mn in 2023 and is expected to exhibit a CAGR of 6.1% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics:
Rising prevalence of diabetes is a key driver fueling growth of the human insulin drug market. According to the International Diabetes Federation, approximately 537 million adults aged 20-79 years were living with diabetes in 2021 worldwide and the number is expected to rise to 643 million by 2030 and 783 million by 2045. Diabetes poses significant health burden globally and requires lifelong treatment with insulin drugs for effective management of blood glucose levels in patients. This growing diabetes patient pool is increasing demand for insulin drugs. Moreover, continuous technological advancements in insulin delivery systems such as insulin pens and pumps are making them more convenient and effective than conventional vial and syringes format. This is positively impacting adoption of insulin drugs.

However, development of alternative treatment options for diabetes is a major challenge for the insulin drug market. For instance, companies are developing oral insulin formulations that could provide an easy replacement for injections. This may hamper demand for traditional injection based insulin products in long run.

SWOT Analysis

Strength: Human insulin drug provides effective treatment for diabetes patients. It helps regulate blood sugar levels in people with type 1 and some type of type 2 diabetes who cannot produce insulin themselves. With years of research and development, human insulin drug production process has become efficient and reliable.

Weakness: Human insulin drug treatment requires regular administration through needles or pumps which many patients find inconvenient and painful. The process also requires strict routine and controlling diet which some patients find difficult to maintain. Production of human insulin drugs can be an expensive process which increases the costs.

Opportunity: Growing prevalence of diabetes globally increases the potential patient base for human insulin drugs. Rapid technological advancements have led to novel drug delivery methods like inhalable insulin and smart insulin pumps which can improve treatment experience. Rise in health awareness and access to healthcare in emerging economies opens new market opportunities.

Threats: Expiry of patents leads to increased competition from biosimilars and generics which pressures profit margins. Stringent regulatory approvals for new treatments also delays market entry. Alternatives like insulin antibodies and islet cell transplant pose potential threats. Rise of sedentary lifestyle related non-communicable diseases increases risk of developing diabetes.

Key Takeaways

The Global Human Insulin Drug Market Share is expected to witness high over the forecast period supported by rising diabetes prevalence worldwide. The global Human Insulin Drug Market is estimated to be valued at US$ 56921.85 Mn in 2024 and is expected to exhibit a CAGR of 6.1% over the forecast period 2024-2031.

The North American region currently dominates the market owing to presence of major players, high healthcare expenditure and increasing diabetic population in the US and Canada. However, Asia Pacific region is expected to emerge as the fastest growing market led by large patient pools, growing economies and improving access and affordability of treatment in countries like India, China and Japan.

Key players operating in the human insulin drug market are Ecolab Inc., Rollins Inc., Rentokil Initial Plc., ServiceMaster Company, LLC, Massey Services Inc., Arrow Exterminators Inc., Sanix Incorporated, Asante Inc., Dodson Pest Control, Inc., Target Specialty Products, Pelsis Ltd., Killgerm Ltd., WinField Solutions, LLC, and Univer Inc. While large players focus on expanding their product portfolios and global presence through mergers and acquisitions, mid-sized and small entities emphasize on niche segments through innovation and customization. The competitiveness in the market compels companies to invest extensively in R&D for developing superior and novel drug delivery technologies.

Get more insights on this topic: https://www.newsanalyticspro.com/human-insulin-drug-market-size-and-share-analysis-growth-trends-and-forecasts/

Explore more information on this topic, Please visit: https://captionssky.com/biologics-a-transformative-field-of-biotechnology/